Newron Pharmaceuticals Logo
IT0004147952

Newron Pharmaceuticals

Ins Portfolio
Über 2000 Dividenden-Werte in einem kostengünstigen ETF. Jetzt entdecken
Anzeige

Kurse werden geladen...

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +42,13(+501,86%). Der Median liegt bei +42,13(+501,86%).

Kaufen
  36
Halten
  17
Verkaufen
  0

Scoring-Modelle

Dividenden-Strategie0 / 15
HGI-Strategie12 / 18
Levermann-Strategie-2 / 13
Powered byaktien.guide

News

  • Foto von Live: SPDR S&P 500 ETF Trust (SPY) Falls From Nvidia, Trade Pressure

    Live: SPDR S&P 500 ETF Trust (SPY) Falls From Nvidia, Trade Pressure

    Live Updates Live Coverage Has Ended Gaines and Losers Today 12:59 pm Winners: APA Corp (APA) up 5.27% Abbott Labs (ABT) up 4.37% Devon Energy (DVN) up 4.17% Marathon Petroleum (MPC) up 3.82% Losers: NVIDIA (NVDA) down 7.53% JB Hunt (JBHT) down 7.49% MD (AMD) down 7.30% Interpublic Group (IPG) down 5.71% China to Fight Until the End 11:42 am According to The White House press release, China now faces up to 245% tariffs on on imports, up from 145% and despite the number increase, China will “ignore” the numbers gain and plans to fight until the end of the tariff war. As of 11:45 am: Nasdaq Composite: -1.48% S&P 500: -0.74% Dow Jones Industrial Average: -.02% Shares of the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) are down 1% in morning trading Wednesday after Nvidia (NASDAQ:NVDA) announced it would take a massive $5.5 billion writedown in the first quarter. The artificial intelligence chipmaker said in a late-afternoon SEC filing yesterday the U.S. government was imposing new trade restrictions on its H20 AI chips that would require it to get a license to export them because they could be used in or diverted to a Chinese supercomputer. Due to the inventory of H20 chips it had on hand, as well as previously agreed to purchase commitments and related reserves, it would be taking the massive writedown. Erecting new barriers Nvidia had designed the H20 specifically to get around export restrictions of its previous chip, the H800. That was the one the Chinese AI firm DeepSeek used to build its R1 large language model that caused a tumult in the market when it launched earlier this year. The chips are cheaper and less powerful than Nvidia’s latest generation Blackwell chips that sell for tens of thousands of dollars. Pricing isn’t so straightforward though as the chips won’t be sold as a standalone product. It hits especially hard because earlier this month, Nvidia stock jumped on reports that Chinese tech companies, including Alibaba (NYSE:BABA), Tencent Holdings (OTC:TCEHY), and TikTok owner ByteDance, had ordered $16 billion worth of the H20 accelerators over the first three months of the year. Nvidia said the write off would be necessary because of the inventory of H20 chips it had on hand, purchase commitments, and related reserves. Nvidia will be reporting its fiscal 2026 first-quarter earnings results on May 26. The Dow Jones Industrial Average is down 200 points, or 0.5%, while the tech-heavy Nasdaq 100 was off almost 2%. Collateral damage The indices are also under pressure because Bloomberg reported little progress has been made between the European Union and the U.S. to resolve their trade differences. While the EU has proposed eliminating all tariffs in both directions, U.S. officials have so far rejected that because of other non-tariff restrictions U.S. goods face, including digital and AI regulations, along with various food standards. Other chipmakers on the S&P 500 are falling as well, including Advanced Micro Devices (NASDAQ:AMD) as it says it will take an $800 million hit due to tariffs. Its shares are down 6% because the new trade restrictions will affect its MI308 chips. Broadcom (NASDAQ:AVGO) is down 2.2% and Micron Technology (NASDAQ:MU) is off 1.7%. The impact of tech stocks on SPY is offsetting the positive news that retail sales rose 1.4% in March, in line with expectations and well ahead of the 0.2% gain seen in February. It was the best reading in more than two years. However, it is likely sales were pulled forward into the month due to consumers buying more ahead of tariffs going into effect. That suggests retail sales in future months won’t be as strong and feeds the fear the U.S. economy is growing slower than analysts had previously predicted. The post Live: SPDR S&P 500 ETF Trust (SPY) Falls From Nvidia, Trade Pressure appeared first on 24/7 Wall St..» Mehr auf 247wallst.com

  • Foto von These Oil Stocks Can Thrive Even With Crude Prices Sinking

    These Oil Stocks Can Thrive Even With Crude Prices Sinking

    Oil prices have tumbled this year. WTI, the primary U.S. oil price benchmark, has plunged from about $80 a barrel in early January to around $60 a barrel.» Mehr auf fool.com

  • Foto von Devon Trades at a Discount to Industry: How to Play the Stock?

    Devon Trades at a Discount to Industry: How to Play the Stock?

    The DVN stock is priced below its industry peers, but with declining earnings estimates, investors should consider waiting for a more appropriate entry point.» Mehr auf zacks.com

Dividenden

Alle Kennzahlen
In 2023 hat Newron Pharmaceuticals +0,0816 Dividende ausgeschüttet. Die letzte Dividende wurde im Juni 2023 gezahlt.

Unternehmenszahlen

Im letzten Quartal hatte Newron Pharmaceuticals einen Umsatz von +4,23 Mrd und ein Nettoeinkommen von +614,09 Mio
(EUR)Dez. 2024
YOY
Umsatz+4,23 Mrd22,42%
Bruttoeinkommen+1,10 Mrd7,17%
Nettoeinkommen+614,09 Mio41,07%
EBITDA+1,86 Mrd4,94%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+17,09 Mrd
Anzahl Aktien
649,00 Mio
52 Wochen-Hoch/Tief
+46,21 - +22,49
DividendenNein
Beta
1,55
KGV (PE Ratio)
+6,57
KGWV (PEG Ratio)
0,45
KBV (PB Ratio)
+1,31
KUV (PS Ratio)
+1,25

Unternehmensprofil

Newron Pharmaceuticals SpA ist ein biopharmazeutisches Unternehmen. Das Unternehmen hat seinen Hauptsitz in Bresso, Mailand, und beschäftigt derzeit 24 Vollzeitmitarbeiter. Das Unternehmen konzentriert sich auf die Entdeckung und Entwicklung von pharmazeutischen Produkten. Die Firma beschäftigt sich mit der Entdeckung und Entwicklung neuer Therapien für Erkrankungen des Zentralnervensystems (ZNS) und Schmerzen. Das Unternehmen führt Phase-III-Studien mit dem Safinamid-Molekül zur Behandlung von Patienten mit der Parkinsonschen Krankheit durch. Newron Pharmaceuticals SpA entwickelt Ralfinamide, ein Molekül für die Behandlung von neuropathischen Schmerzen. Weitere Projekte wie HF0220 zur Neuroprotektion, NW-3509 zur Behandlung von Schizophrenie sowie Pruvanserin und Sarizotan zur Behandlung von ZNS-Erkrankungen befinden sich in verschiedenen Stadien der präklinischen und klinischen Entwicklung.

Name
Newron Pharmaceuticals
CEO
Clay M. Gaspar
SitzOklahoma City, ok
Italien
Website
Industrie
Öl, Gas und nicht erneuerbare Brennstoffe
Börsengang
Mitarbeiter2.300

Ticker Symbole

BörseSymbol
XETRA
NP5.DE
SIX
NWRN.SW
London Stock Exchange
0QOI.L
Frankfurt
NP5.F
Düsseldorf
NP5.DU
London
0QOI.L
München
NP5.MU
NYSE
DVN
Set
TTT.BK
Pnk
TINLY

Assets entdecken

Shareholder von Newron Pharmaceuticals investieren auch in folgende Assets

🍪

Parqet nutzt Cookies.Erfahre Mehr